IBRX - ImmunityBio, Inc.
9
-1.000 -11.111%
Share volume: 32,792,651
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.44%
PREVIOUS CLOSE
CHG
CHG%
$10.00
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-12-2024 | 11-12-2024 | 03-03-2025 | 05-12-2025 | 08-05-2025 | 11-05-2025 | 02-23-2026 | |
| Assets | |||||||||
| Total Assets | 400.679 M | 444.325 M | 364.570 M | 382.933 M | 303.759 M | 402.076 M | 518.987 M | 501.898 M | |
| Current Assets | 195.722 M | 242.830 M | 163.150 M | 184.586 M | 109.163 M | 208.132 M | 329.497 M | 314.875 M | |
| Inventories | 0.000 | 1.811 M | 1.958 M | 8.272 M | 8.444 M | 6.640 M | 6.703 M | 910.000 K | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 37.460 M | 87.875 M | 18.401 M | 6.381 M | 931.000 K | 16.000 M | 197.572 M | 154.484 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 133.035 M | 130.104 M | 111.966 M | 143.428 M | 60.660 M | 137.658 M | 60.241 M | 88.334 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 143.517 M | 141.956 M | 139.285 M | 137.094 M | 135.270 M | 133.004 M | 129.597 M | 114.264 M | |
| Other Assets | 61.440 M | 59.539 M | 62.135 M | 61.253 M | 59.326 M | 60.940 M | 59.893 M | 72.759 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 400.679 M | 444.325 M | 364.570 M | 382.933 M | 303.759 M | 402.076 M | 518.987 M | 501.898 M | |
| Total liabilities | 1.092 B | 1.142 B | 1.109 B | 871.062 M | 894.241 M | 971.895 M | 1.042 B | 1.001 B | |
| Total current liabilities | 53.759 M | 62.110 M | 60.960 M | 54.944 M | 49.205 M | 50.644 M | 57.134 M | 61.754 M | |
| Accounts Payable | 47.677 M | 55.861 M | 53.927 M | 47.478 M | 41.745 M | 43.252 M | 49.818 M | 54.219 M | |
| Other liabilities | 187.401 M | 123.333 M | 74.997 M | 531.714 M | 63.032 M | 122.118 M | 168.314 M | 138.010 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 850.502 M | 956.260 M | 972.775 M | 284.404 M | 782.004 M | 799.133 M | 816.949 M | 801.708 M | |
| Other liabilities | 187.401 M | 123.333 M | 74.997 M | 531.714 M | 63.032 M | 122.118 M | 168.314 M | 138.010 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -692.012 M | -698.387 M | -745.148 M | -489.098 M | -591.431 M | -570.749 M | -524.319 M | -500.469 M | |
| Common stock | 2.404 B | 2.532 B | 2.571 B | 2.885 B | 2.894 B | 3.014 B | 3.135 B | 3.197 B | |
| Retained earnings | -3.096 B | -3.230 B | -3.316 B | -3.375 B | -3.505 B | -3.597 B | -3.665 B | -3.727 B |